Suppr超能文献

水肿、实体器官移植与雷帕霉素哺乳动物靶点抑制剂/增殖信号抑制剂(mTOR-I/PSIs)

Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs).

作者信息

Gharbi Chems, Gueutin Victor, Izzedine Hassan

机构信息

Department of Nephrology , Pitié Salpetriere Hospital , Paris , France.

出版信息

Clin Kidney J. 2014 Apr;7(2):115-20. doi: 10.1093/ckj/sfu001. Epub 2014 Feb 24.

Abstract

Mammalian target of rapamycin inhibitor (mTOR-I)/proliferation signal inhibitors (PSI) including sirolimus and everolimus represent a new class of drugs increasingly used in solid-organ transplantation as alternatives to calcineurin inhibitors for patients with renal dysfunction, transplant coronary arterial vasculopathy or malignancy. The most frequently occurring mTOR-I/PSI-related adverse events are similar to those associated with other immunosuppressive therapies, but some side effects are more characteristic of proliferation signal inhibitors (e.g. lymphocele, arthralgia, oedema and hyperlipidaemia). The present paper review incidence, clinical presentation and mechanism of oedema within the clinical experience of mTOR-I/PSI in solid organ transplantation.

摘要

哺乳动物雷帕霉素靶蛋白抑制剂(mTOR-I)/增殖信号抑制剂(PSI),包括西罗莫司和依维莫司,代表了一类新型药物,越来越多地用于实体器官移植,作为肾功能不全、移植冠状动脉血管病变或恶性肿瘤患者钙调神经磷酸酶抑制剂的替代品。最常发生的mTOR-I/PSI相关不良事件与其他免疫抑制疗法相关的不良事件相似,但有些副作用更具增殖信号抑制剂的特征(如淋巴囊肿、关节痛、水肿和高脂血症)。本文在实体器官移植中mTOR-I/PSI的临床经验范围内综述水肿的发生率、临床表现及机制。

相似文献

3
Safety of mTOR inhibitors in adult solid organ transplantation.
Expert Opin Drug Saf. 2016;15(3):303-19. doi: 10.1517/14740338.2016.1132698. Epub 2016 Jan 28.
4
The role of proliferation signal inhibitors in post-transplant malignancies.
Nephrol Dial Transplant. 2007 May;22 Suppl 1:i11-6. doi: 10.1093/ndt/gfm084. Epub 2007 Mar 14.
5
Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
Nephrol Dial Transplant. 2006 Jul;21 Suppl 3:iii14-7. doi: 10.1093/ndt/gfl296.
6
Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation.
World J Transplant. 2016 Mar 24;6(1):183-92. doi: 10.5500/wjt.v6.i1.183.
7
Sirolimus: a novel immunosuppressive drug in heart transplantation.
Recent Pat Cardiovasc Drug Discov. 2009 Nov;4(3):187-91. doi: 10.2174/157489009789152294.
8
Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
Nefrologia. 2013;33(3):297-300. doi: 10.3265/Nefrologia.pre2013.Jan.11439.
9
Use of sirolimus in solid organ transplantation.
Drugs. 2007;67(3):369-91. doi: 10.2165/00003495-200767030-00004.
10
Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
Clin Transplant. 2015 Jul;29(7):654-63. doi: 10.1111/ctr.12559. Epub 2015 Jun 10.

引用本文的文献

1
MTOR maintains endothelial cell integrity to limit lung vascular injury.
J Biol Chem. 2024 Dec;300(12):107952. doi: 10.1016/j.jbc.2024.107952. Epub 2024 Nov 6.
2
Sirolimus potentiated angioedema: A case report and review of the literature.
Open Med (Wars). 2024 Jan 9;19(1):20230884. doi: 10.1515/med-2023-0884. eCollection 2024.
3
Update on Treatment of Hypertension After Renal Transplantation.
Curr Hypertens Rep. 2021 May 7;23(5):25. doi: 10.1007/s11906-021-01151-8.
4
A Pediatric Case of Sirolimus-Associated Pneumonitis After Kidney Transplantation.
J Pediatr Pharmacol Ther. 2020;25(5):459-464. doi: 10.5863/1551-6776-25.5.459.
5
Exacerbation of Chikungunya Virus Rheumatic Immunopathology by a High Fiber Diet and Butyrate.
Front Immunol. 2019 Nov 26;10:2736. doi: 10.3389/fimmu.2019.02736. eCollection 2019.
6
Predictors of symptomatic lymphocele after kidney transplantation.
Int Urol Nephrol. 2019 Dec;51(12):2161-2167. doi: 10.1007/s11255-019-02269-0. Epub 2019 Sep 5.

本文引用的文献

1
A case of everolimus-associated chylothorax in a cardiac transplant recipient.
Transplant Proc. 2013 Oct;45(8):3144-6. doi: 10.1016/j.transproceed.2013.08.082.
3
Everolimus monotherapy or combined therapy in liver transplantation: indications and results.
Transplant Proc. 2013 Jun;45(5):1971-4. doi: 10.1016/j.transproceed.2013.01.075.
4
Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study.
Am J Transplant. 2013 Jul;13(7):1734-45. doi: 10.1111/ajt.12280. Epub 2013 May 28.
5
Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
Clin Transplant. 2013 Mar-Apr;27(2):217-26. doi: 10.1111/ctr.12045. Epub 2012 Dec 12.
6
Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Transplant Proc. 2012 Dec;44(10):2966-70. doi: 10.1016/j.transproceed.2012.06.072.
7
Everolimus-induced lymphedema in a renal transplant recipient: a case report.
Exp Clin Transplant. 2012 Jun;10(3):296-8. doi: 10.6002/ect.2011.0139.
8
A retrospective 12-month study of conversion to everolimus in lung transplant recipients.
Transplant Proc. 2011 Sep;43(7):2693-8. doi: 10.1016/j.transproceed.2011.06.028.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验